Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Initial Safety and Performance of the CellFX® Nano-PFA 360 Catheter Endocardial Ablation System for the Treatment of Atrial Fibrillation

NCT06696170 is registered in ClinicalTrials.gov with Pulse Biosciences, Inc. as lead sponsor.

NCT NCT06696170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06696170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Initial Safety and Performance of the CellFX® Nano-PFA 360 Catheter Endocardial Ablation System for the Treatment of Atrial Fibrillation
Lead sponsor
Pulse Biosciences, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
July 25, 2024
Completion date
July 25, 2026
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation paroxysmal, cardiac ablation, cardiac arrhythmia